# Avalo Therapeutics Inc. (AVTX) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $19.23, market value $1.0 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Avalo Therapeutics Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 17479.7×**. Each dollar of revenue is priced at 17479.7×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 2.3×**. The shares trade at 2.3× book value; book value is a meaningful part of the valuation.

## Profitability
- **Return on equity: -94.2%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: -70.7%**. Return on all capital, debt included, is -70.7%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -67.2%**. Each dollar of assets produces -67.2% of profit.

## Growth
- **Revenue growth (1 yr): -86.6%** (3-yr -85.2%/yr, 5-yr -61.2%/yr). Revenue fell 86.6% over the last year, against -61.2% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): 72.1%**. Earnings per share rose 72.1%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Debt to equity: 0.17**. Debt is 0.17 times equity: a conservative balance sheet.
- **Net debt / EBITDA: 0.0×**. It would take 0.0 years of operating earnings to repay net borrowings, within the comfortable range.
- **Current ratio: 8.14** (quick 8.14). Current assets cover the next year's liabilities 8.14 times.
- **Altman Z-score: 18.41**. A Z-score of 18.41 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 1/9**. 1 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Avalo Therapeutics Inc. does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): 89.3%** (YTD 5.9%, 3-mo 46.8%). The shares are up 89.3% over twelve months including dividends.
- **From 52-week high: -20.8%** (101.6% above the low). Trading 21% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 49**. An RSI of 49 is neutral.
- **Beta (1 yr): 1.28** (volatility 87%). Beta of 1.28 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=AVTX · Page: https://foliofundamentals.com/stocks/avtx

Not investment advice.